Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and…
Quince Therapeutics Announces Major Clinical and Corporate Milestones Alongside Q2 2025 Financial Results Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to harnessing a patient’s own biology for…
Enanta Pharmaceuticals Reports Fiscal Third Quarter 2025 Results and Provides Pipeline Progress Update Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to the discovery and development of small…
Laxxon Medical Achieves Major Product Development Milestone with Novel SPID®-Based Oral Modified-Release Formulation of Veru’s Enobosarm Laxxon Medical Corp., a pioneering pharmaceutical technology company specializing in next-generation oral drug delivery…
NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive Chairman, Marking a Key Step in Leadership Succession for Continued Growth in the Radiopharmaceutical Sector NorthStar Medical Technologies, LLC, a recognized global…
Equillium Secures Up to $50 Million in Private Placement Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, Into Clinical Development Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator dedicated…
Thermo Fisher Scientific Secures FDA Approval for NGS-Based Companion Diagnostic to Support New HER2-Targeted NSCLC Therapy Thermo Fisher Scientific Inc. (NYSE: TMO), the global leader in serving science, has announced…
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing…
Tahoe Therapeutics Secures $30 Million to Build the World’s Largest Dataset for Training AI-Powered Human Cell Models, Aiming to Transform Precision Medicine Tahoe Therapeutics, a biotechnology company at the intersection…
Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company…
Newron Announces Landmark Preclinical Study Supporting Evenamide’s Potential to Transform Schizophrenia Treatment Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for…
Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company…